FOLH1 and neoplasm: Moreover, a prospective analysis of patients (n = 19) undergoing [177Lu]Lu-PSMA-617 therapy for mCRPC suggested that for both full-length AR and the truncated AR splice variant, AR-V7, mRNA copy numbers might serve as prognostic biomarkers for high tumor burden in patients with mCRPC prior to initiating [177Lu]Lu-PSMA-617 treatment, although further study is required (81).